Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Autologous glioma tumour cells treated with antisense molecule directed against the insulin-like growth factor type 1 receptor

EU orphan designation number: EU/3/18/2061   
Active ingredient: Autologous glioma tumour cells treated with antisense molecule directed against the insulin-like growth factor type 1 receptor
Indication: Treatment of glioma
Sponsor: Pharma Gateway AB
Johanneslundsvägen 2, Hammarby, 194 61 Upplands Väsby, Stockholms Lan, Sverige

  

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
28/08/2018 Orphan designation EMA/OD/049/18 (2018)5739 of 24/08/2018